DUBLIN, June 30, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/qzh5gg/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) Market - Forecast to 2019" report to their offering.
Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand.
The World Health Organization (WHO) reported that in 2010, approximately 1.9% of women aged between 20 years and 44 years were unable to have their first child and 10.5% of women who had already conceived were unable to conceive for the subsequent times. Thus, high global infertility rates will continue to provide newer growth opportunities to this market. Some other factors contributing to the growth of the human reproductive technologies market include increasing morbidity rate of infertility in both males and females, rise in awareness about the available technologies for treating problems related to reproduction, rising prevalence of unwanted pregnancies, and overall advancement in the available technologies to control reproduction.
Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure.
Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs).
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment
Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies
Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography
Chapter 7 Recommendations
Chapter 8 Company Profiles
- Abbott Laboratories, Inc.
- Actavis, Inc.
- Bayer AG
- Church & Dwight, Co. Inc.
- Cook Medical, Inc.
- Ferring International Center S.A.
- Johnson & Johnson
- Merck & Co., Inc.
- Merck Serono
- Pfizer, Inc.
- Reckitt Benckiser Group plc
- Teva Pharmaceutical Industries Ltd.
- Warner Chilcott plc
For more information visit http://www.researchandmarkets.com/research/qzh5gg/human
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets